Xigris worked, so why did Lilly withdraw the drug?
This article was originally published in Scrip
Executive Summary
The clinical trial that caused Eli Lilly abruptly to withdraw its septic shock treatment Xigris (drotrecogin alfa [activated]) from all markets in October 2011 (scripintelligence.com, 27 October 2011) may have been flawed, or at least atypical of clinical practice, according to a recent meta-analysis of Xigris studies.
You may also be interested in...
Adrenomed Treads A New Path In Septic Shock
German firm Adrenomed has received new funding to push its innovative antibody for septic shock further into development. The company talks to Scrip about how it works, and why it won’t allow the asset to be a victim of strategic decision making.
Gender Diversity In Pharma: Caught Between Desire And Reality
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
Women In High Places: Slow Progress In Pharma
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.